Treatment Plan: 56F, Stage III Breast Cancer - ER+/PR-/FGFR2+, Family History, Low Socioeconomic Background

Understanding the Tumor Biology

• ER+/PR- tumors have lower sensitivity to endocrine therapy alone compared to ER+/PR+ tumors
• FGFR2 alteration is a known driver of resistance to endocrine therapy and CDK4/6 inhibitors - it activates an escape pathway that bypasses estrogen receptor signaling
• Family history of cancer warrants BRCA1/2 and BRCA2 germline testing (and possibly PALB2, ATM), as this changes systemic therapy options
• Post-menopausal at 56 - this affects the choice of endocrine backbone

Line of Treatment

Phase 1: Neoadjuvant Systemic Therapy (Before Surgery)

• Neoadjuvant chemotherapy is typically recommended for high-risk Stage III ER+ breast cancer before surgery, especially if the tumor is large or node-positive
• Regimen: AC-T (Adriamycin/Cyclophosphamide x4 cycles, then Taxane x4 cycles) - this is the most widely used and affordable regimen
• Neoadjuvant endocrine therapy (letrozole alone) is an alternative for patients who cannot tolerate chemotherapy or refuse it, but response rates are lower and slower

Phase 2: Surgery

• Modified Radical Mastectomy (MRM) - most common for locally advanced disease; more affordable than breast-conserving approaches requiring radiation boost
• Breast-Conserving Surgery (BCS) + radiation - if the tumor responds well and downstages adequately; requires access to radiation facility

Phase 3: Radiation Therapy

• Post-mastectomy radiation to the chest wall and regional nodes (PMRT) is indicated for Stage III disease
• Essential for locoregional control

Phase 4: Adjuvant Systemic Therapy (Long-term)

• Aromatase Inhibitor (AI): Letrozole or Anastrozole x 5-10 years (post-menopausal)
• Generic letrozole is widely available and affordable (as low as ₹50-200/month in India)

• For high-risk Stage III ER+/HER2- disease, adjuvant abemaciclib (monarchE trial) or ribociclib (NATALEE trial) for 2-3 years significantly reduces recurrence risk
• Abemaciclib (Verzenio): ~$1,500-2,000/month brand; generic versions are emerging in India (Cyclolib, ~₹8,000-15,000/month - substantially cheaper)
• Ribociclib (Kisqali): Similar pricing; also increasingly available as generics in India
• For a low-income patient, generic abemaciclib or palbociclib (available under names like Ibrance-generic) is the most cost-accessible CDK4/6 inhibitor

• Erdafitinib (Balversa) is an FDA-approved pan-FGFR inhibitor (FGFR1-4), currently approved for urothelial carcinoma with FGFR alterations
• In breast cancer with FGFR alterations, trials such as RAGNAR (Lancet Oncol, 2023) showed activity, and a Phase Ib trial (Clin Cancer Res, 2025) tested fulvestrant + palbociclib + erdafitinib in HR+/HER2- metastatic breast cancer with FGFR alterations - showing feasibility and no new toxicities
• A co-clinical trial (npj Precision Oncology, 2025) using SERD + CDK4/6i + FGFR inhibitor (rogaratinib) showed responses in FGFR-amplified tumors that were PIK3CA/ESR1 wild-type
• Current recommendation: FGFR inhibitor-based combinations are NOT yet standard adjuvant therapy for breast cancer. This patient should be referred to a clinical trial if available (especially in academic centers)

Treatment Algorithm Summary

Germline Testing Recommendation

• BRCA1/2 germline testing - if positive, adjuvant olaparib (Lynparza) for 1 year (OlympiA trial) is indicated, and also informs family members
• Testing is available at reduced/subsidized cost through government cancer institutes in India (Tata Memorial Hospital, AIIMS)

Affordability - Practical Guidance

Available Financial Relief Pathways (India context)

Cost-Effective Treatment Sequence for Low-Income Patient

1. Chemotherapy (AC-T): ~₹30,000-60,000 total at government hospital (vs ₹3-5L private)
2. Surgery (MRM): Free at government cancer center
3. Radiation: Free at AIIMS/TMH/Regional Cancer Centers
4. Letrozole (generic): ~₹2,400/year
5. Generic abemaciclib/palbociclib: ~₹72,000-1,44,000/year (vs ₹18L brand) - seek PAP or Ayushman coverage
6. BRCA test: ~₹8,000-15,000 (or free at some government centers)

Special Considerations for This Patient

1. Family history - full pedigree assessment; refer first-degree relatives for BRCA counseling
2. ER+/PR- biology - lower endocrine sensitivity; more aggressive approach with CDK4/6 inhibitor is well-justified
3. FGFR2 - currently best addressed through clinical trial enrollment; erdafitinib + endocrine + CDK4/6i triple combinations are being studied
4. Psychosocial support - low socioeconomic status + family cancer history creates significant distress; connect with oncology social worker and NGO support (CanSupport, Indian Cancer Society)
5. Nutritional assessment - malnutrition common in low-income patients undergoing chemotherapy; nutritional supplementation programs available at TMH/AIIMS

Key Recent Evidence

• Gonzalez-Ericsson et al., Clin Cancer Res 2025 - Phase Ib trial of fulvestrant + palbociclib + erdafitinib in HR+/HER2- breast cancer with FGFR alterations: feasible, well-tolerated
• Pant et al., Lancet Oncol 2023 (RAGNAR trial) - erdafitinib showed clinical activity across solid tumors with FGFR alterations including breast cancer
• monarchE (J Clin Oncol 2024) - abemaciclib + ET in high-risk Stage III ER+ breast cancer: sustained 5-year IDFS benefit